drugset / Trial / NCT04488159
Immunoscore As Decision Guidance for Adjuvant Chemotherapy in Colon Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The overall aim of this study is to prospectively validate the superiority of the Immunoscore as a decision guidance for adjuvant chemotherapy in stage III colon cancer patients, in comparison to the conventional TNM-based high- or low-risk classification.
Timeline
- Start
- 2024-12-01
- Primary completion
- 2025-12-01
- Completion
- 2026-06-01
Outcome
Outcome not reported
Stopped (Business): “Lack of funding.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Leucovorin | Small molecule | 200 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 400 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 600 mg/m2 | Intravenous |